We at Mindpeak GmbH are very proud to announce the CE-mark of "Mindpeak Breast Ki-67 HS", the first AI software which directly proposes automatically recognized and analyzed hotspots to the pathologist on whole-slide images. This “0-click” solution is a milestone in the development of tools to assist pathologists. When pathologists open a case for the first time, our AI has already pre-processed and analyzed hotspots and the result only needs to be reviewed.
Mindpeak announces first CE-marked fully automated software to support breast cancer tissue diagnosis
Related reading
.webp)
AstraZeneca X Mindpeak: Transforming Early Breast Cancer Detection with AI
We’re beyond excited to partner with AstraZeneca to evaluate and deploy our AI-powered solution for early breast cancer detection in multiple centers around the globe.
The collaboration investigates the role of AI in enhancing diagnostic accuracy, optimizing pathology workflows, and supporting pathologists in detecting invasive breast cancer and Ductal Carcinoma in Situ (DCIS) more resource-efficiently and at an earlier stage.
Breast cancer is the most common cancer among women worldwide, with over 2.3 million new cases annually. Early and accurate diagnosis is critical, yet many healthcare systems struggle with pathologist shortages and increasing case volumes — to delays in detection and treatment.
By integrating our AI products into digital pathology workflows, we strive to accelerate diagnoses, boost efficiency, and ultimately improve patient outcomes.This is a major milestone in the future of AI-driven digital pathology — and we’re just getting started!
Read the full article here: https://lnkd.in/eNSA2ZHg
New partnership announcement
Mindpeak GmbH and Lumea announce a strategic partnership to advance AI in pathology!
This partnership brings Mindpeak’s AI applications to Lumea’s BxLink platform, offering users broader access to state-of-the-art tools for improved diagnostic precision and enhanced lab efficiency.
Read more about this exciting partnership: https://lnkd.in/gnWv9pyf
ZEISS and Mindpeak partner to advance Multiplex Immunofluorescence (mIF) solutions for pathology
The future of pathology is here!
ZEISS Microscopy and Mindpeak GmbH partner to develop an integrated Multiplex Immunofluorescence (mIF) solution, combining ZEISS’s advanced instruments with Mindpeak’s AI-powered pathology analysis.
Mindpeak’s expertise in AI-based image analysis of pathological tissues, particularly through its established algorithms for clinical routine applications, complements ZEISS's advanced instruments and software for research applications of mIF. The joint solution will integrate both companies' existing offerings to enhance the value for the users and address multiple market segments.The partnership combines complementary competencies and expands both companies’ reach in the growing mIF market.
Read more: https://lnkd.in/g6FknEqP
Ready to advance your diagnostics
Connect with our team to explore how precision pathology works in your setting